Olema Pharmaceuticals, Inc. $OLMA Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC lowered its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 28.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 615,470 shares of the company's stock after selling 243,082 shares during the period. Squarepoint Ops LLC owned about 0.70% of Olema Pharmaceuticals worth $7,700,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of OLMA. Arizona State Retirement System lifted its stake in Olema Pharmaceuticals by 39.2% in the 2nd quarter. Arizona State Retirement System now owns 14,430 shares of the company's stock valued at $181,000 after buying an additional 4,062 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Olema Pharmaceuticals during the 2nd quarter worth approximately $220,000. California State Teachers Retirement System raised its holdings in shares of Olema Pharmaceuticals by 1,773.9% during the second quarter. California State Teachers Retirement System now owns 732,285 shares of the company's stock valued at $9,161,000 after acquiring an additional 693,206 shares during the last quarter. Readystate Asset Management LP acquired a new position in shares of Olema Pharmaceuticals during the second quarter valued at approximately $7,429,000. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Olema Pharmaceuticals in the second quarter valued at approximately $690,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Olema Pharmaceuticals Price Performance

Olema Pharmaceuticals stock opened at $10.69 on Friday. Olema Pharmaceuticals, Inc. has a 12-month low of $6.65 and a 12-month high of $36.26. The stock has a market cap of $935.38 million, a P/E ratio of -5.04 and a beta of 1.98. The company has a 50-day moving average price of $11.29 and a 200 day moving average price of $13.50. The company has a current ratio of 8.86, a quick ratio of 8.86 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.06). Sell-side analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.43 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. lowered their price target on Olema Pharmaceuticals from $52.00 to $46.00 and set an "overweight" rating on the stock in a research note on Thursday, August 13th. HC Wainwright reduced their price objective on Olema Pharmaceuticals from $38.00 to $36.00 and set a "buy" rating for the company in a research note on Tuesday, August 11th. Citigroup decreased their price objective on Olema Pharmaceuticals to $59.00 and set a "buy" rating on the stock in a report on Tuesday, August 11th. Wall Street Zen cut shares of Olema Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Saturday, July 25th. Finally, Weiss Ratings lowered shares of Olema Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a report on Monday, August 31st. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $42.40.

Insider Activity at Olema Pharmaceuticals

In related news, Director Cyrus Harmon sold 12,500 shares of the company's stock in a transaction that occurred on Thursday, July 23rd. The stock was sold at an average price of $11.58, for a total value of $144,750.00. Following the transaction, the director directly owned 715,270 shares in the company, valued at approximately $8,282,826.60. This represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 12.56% of the company's stock.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

Want to see what other hedge funds are holding OLMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.